CONfident Treatment Decisions in Living With Rheumatoid Arthritis

Pilot test the novel educational patient-directed intervention to demonstrate the feasibility
of the novel educational approaches developed in improving patient's willingness to achieve
remission or low disease activity in RA. Upon agreement to participate, the patient
participants will provide information on their treating physician. This information will be
used to invite physicians to complete the physician-educational intervention and offered CME
credits for completing the activity.

The investigators will recruit participants from a patient registry (1:1 intervention:
control) that meet the eligibility criteria. The recruited patients will complete the
educational intervention (if randomized to the intervention arm) and the study outcomes will
be collected immediately after the intervention and also after the patients most proximate
rheumatologist visit (up to 6-months later).

Inclusion Criteria:

- Have a patient-reported diagnosis of RA

- Most recent RAPID3 > 12 collected in the last 6 months

- Have not changed RA medication in the last 6 months

- Taking medications that are commonly used in RA (e.g. methotrexate, sulfasalazine,
hydroxychloroquine (plaquenil), leflunomide (arava), etanercept (enbrel), adalimumab
(Humira), tofacitinib (xeljanz), actemra (tocilizumab), sarilumab (Kevzara) ,
infliximab (remicade), golimumab (Simponi), rituximab (rituxan), abatacept (Orencia),
and certolizumab (Cimzia))

Exclusion Criteria:

- Does not meet inclusion criteria

- Age < 18